Arrowhead Pharmaceuticals (ARWR) FY2019 results: revenue $169 million, up 945.7% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $169 million for fiscal 2019, the year ended 30 September 2019, up 945.7% on the year before. Net income was $68 million, and diluted earnings per share $0.69. The figures are the company's own, from the 10-K it filed with the SEC on 25 November 2019.
Revenue
$169 million
+945.7% on the year
FY2012FY2019
Operating margin
36.3%
-346.5% a year earlier
FY2012FY2019
Net income
$68 million
FY2012FY2019
Diluted EPS
$0.69
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
169
16.1
31.4
+945.7%
Research and development
81.0
53.0
50.9
+53.0%
Operating income
61.2
-55.9
-37.0
Operating margin
36.3%
-346.5%
-117.8%
Pre-tax income
68.1
-54.4
-34.4
Income tax
0.2
0.0
0.0
+7,150.0%
Effective tax rate
0.3%
n/a
n/a
Net income
68.0
-54.5
-34.4
Net margin
40.3%
-337.3%
-109.5%
Diluted EPS
$0.69
-$0.65
-$0.47
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
173
-47.2
-23.9
Capital expenditure
12.0
1.4
7.9
+744.4%
Free cash flow
161
-48.6
-31.9
Free cash flow margin
95.4%
-301.3%
-101.4%
Cash from investing
-47.7
-7.4
-48.6
Cash from financing
66.4
60.0
12.1
+10.7%
Depreciation and amortisation
2.7
3.0
3.0
-10.0%
Share-based compensation
12.4
8.5
7.9
+46.6%
Diluted shares, weighted
99m
84m
74m
+17.9%
Shares outstanding at period end
96m
89m
75m
+7.9%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
245
95.8
81.4
+155.3%
Non-controlling interest
-0.6
-0.6
-0.6
Debt
0.0
2.1
2.3
Other liabilities
106
14.3
20.8
+641.6%
Total liabilities and equity
350
112
104
+213.5%
Fixed assets
23.2
13.9
15.5
+66.6%
Intangible assets
17.1
18.8
20.5
-9.1%
Securities held for sale or to maturity
81.1
46.4
40.8
+74.7%
Cash and equivalents
222
30.1
24.8
+636.1%
Receivables
0.7
0.3
0.1
+102.0%
Other assets
6.0
2.0
2.4
+194.0%
Total assets
350
112
104
+213.5%
10-K for the year ended 30 September 2019, filed 25 November 2019: the filing.